Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermo Fisher beats expectations in Q2

This article was originally published in Clinica

Executive Summary

Thermo Fisher Scientific reported second-quarter revenues of $3.24bn (+4% year-on-year) and adjusted earnings of $1.32 per share (+8%), beating analyst consensus of $3.22bn and $1.30, respectively. The firm lowered its revenue guidance to $12.83-12.95bn (from $12.84-13.00bn) on foreign exchange headwinds; but upped the lower end of its EPS guidance to $5.29-5.39 (from $5.27-5.39). “Management continues to execute well in a challenging environment via share gains and solid cost controls,” noted Goldman Sachs analyst Isaac Ro. Meanwhile, Jefferies analyst Brandon Couillard raised his share price target to $102, from $95. The firm’s stock is currently trading at around $90.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel